A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219)

Inclusion Criteria:

- Participant enrolled at birth should be at least 37 weeks gestation and ≥3 kg of
weight

- Scheduled to receive general anesthesia AND must have at least one of the following
risk factors for post-operative nausea and vomiting (PONV) in addition to receiving
general anesthesia:

1. scheduled to have a surgery with an associated risk of PONV: tonsillectomy,
adenoidectomy, strabismus surgery, dental surgery, hydrocelectomy, orchidopexy
or herniorraphy; OR

2. scheduled to have an operative procedure associated with PONV:

intraoperative opioid use or anticipated opioid administration within the first 24 hours
following surgery.

Exclusion Criteria:

- Emergency surgery for a life-threatening condition

- Scheduled to receive propofol for maintenance of anesthesia (Note: propofol is
permitted for induction of anesthesia).

- Expected to receive opioid antagonists (e.g., naloxone, naltrexone) or

benzodiazepine antagonists (e.g., flumazenil)

- Scheduled to undergo cardiac or neurosurgery

- Vomiting caused by any organic etiology (such as gastric outlet

obstruction or small bowel obstruction)

- Vomiting within 24 hours prior to surgery

- Nasogastric or oral gastric tube intra- or post-operatively for suctioning

gastric contents

- Active infection (e.g., pneumonia), congestive heart failure,

bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal
obstruction) except for malignancy, or a history of any illness which in the opinion of
the investigator, might confound the results of the study or pose unwarranted risk to the
participant

- Use of any illicit drugs, including marijuana or has current evidence of alcohol
abuse